Inclusion Criteria:

- 20~75 years

- Histologically or cytologically confirmed solid tumors that have failed to standard
therapy or for which no life prolonging treatment exists

- ECOG PS 0-2

- Life expectancy 12 weeks

- Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL,
Prothrombin time, Activated partial thromboplastin time: normal range

- Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤
3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases)

- serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min

- PT, APTT: normal range

- Signed a written informed consent

Exclusion Criteria:

- Brain or Leptomeningeal metastases

- History of Ischemic heart disease(e.g., myocardial infarction, unstable angina
pectoris) or Clinically significant heart disease such as NYHA Class III and IV
Congestive atrial arrhythmias, within 6 months prior to first dose of study drug

- Stable angina pectoris shown symptoms within 6 months prior to first dose of study
durg, or Clinically significant abnormality on EKG or echocardiogram(e.g., LVEF < 50%
or clinically significant heart wall abnormality or heart muscle damage)

- Cerebrovascular disease such as stroke

- Grade 2 or greater motor or sensory peripheral neuropathy

- Uncontrolled hypertension(greater than 150 mmHg systolic or 100 mmHg diastolic
regardless of medication)

- acute infection or blooding tendencies that would preclude study compliance

- Serious vascular disease such as Aortic aneurysm

- Other psychiatric disorders or other conditions that would preclude study compliance

- Receiving anticoagulation with warfarin, heparin, etc.

- Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 3 weeks
prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks
for radiation therapy)

- Other concurrent antitumor therapy

- Patients with serious hypersensitivity history or allergy to CKD-516

- Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective
contraception

- Participation in a clinical trial within 4 weeks of first dose of study drug

- Patients judged to be inappropriate for this study by the investigator with other
reasons